⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SPRY News
ARS Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
SPRY
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
globenewswire.com
SPRY
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
globenewswire.com
SPRY
Spryte Medical Announces First Participants Enrolled in the INSYTE Trial at Baptist Health Jacksonville
globenewswire.com
SPRY
Spryte Medical Announces First Participants Enrolled in the INSYTE Trial at Baptist Health Jacksonville
globenewswire.com
SPRY
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences
globenewswire.com
SPRY
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
globenewswire.com
SPRY
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
globenewswire.com
SPRY
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
globenewswire.com
SPRY